Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 02, 2020
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: December 06, 2018
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Journal: Cancer chemotherapy and pharmacology
Published: August 28, 2017
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Journal: British journal of clinical pharmacology
Published: February 27, 2017
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Journal: The Lancet. Oncology
Published: January 12, 2017
Clinical development of new drug-radiotherapy combinations.
Journal: Nature reviews. Clinical oncology
Published: June 02, 2016
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Journal: International journal of cancer
Published: October 06, 2015
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 26, 2015
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 16, 2014
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: May 06, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026